Liraglutide (Saxenda) vs orforglipron
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
Liraglutide (Saxenda)
Marketed by Novo Nordisk
NCT00781937 · Phase 3 · completed
The trial randomly assigned 212 participants to liraglutide and 210 to placebo in a double-blind, placebo-controlled design, with objective body-weight outcomes assessed at week 56. All three prespecified primary comparisons favored liraglutide and were statistically significant (each p<0.0001), supporting a strong evidence grade.
Next expected readout: December 2026 · NCT07225816 (registry estimate)
Reported efficacy
Change in BMI SDS (Week 0, Week 56): Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54) (met)
Result source: NCT02918279
orforglipron · Foundayo
Marketed by Eli Lilly and partners
NCT05803421 · Phase 3 · completed
ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.
Next expected readout: February 2027 · NCT06672549 (registry estimate)
Reported efficacy
Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)
Result source: NCT05872620
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Liraglutide (Saxenda) | orforglipron |
|---|---|---|
| Body weight, % change | -8.0% vs -2.6%−5.4 vs placeboNCT0127221920 other results
| -7.9% vs -0.6%−7.3 vs placeboNCT0593138011 other results
|
| Weight loss of 5% or more | 63.2% vs 27.1%+36.1 vs placeboNCT012722194 other results
| 58.3% vs 15%+43.3 vs placeboNCT0593138010 other results
|
| Weight loss of 10% or more | 33.1% vs 10.6%+22.5 vs placeboNCT012722193 other results
| 38.3% vs 3.3%+35 vs placeboNCT0593138010 other results
|
| Waist circumference, change (cm) | -6.9 vs -3.4−3.5 vs placeboNCT0127221924 other results
| -5.7 vs -0.1−5.6 vs placeboNCT0593138012 other results
|
Body weight, % change
- Liraglutide (Saxenda)
- -8.0% vs -2.6%−5.4 vs placeboNCT01272219
20 other results
- -6.1% vs -0.1% NCT00781937
- -5.9% vs -2% NCT01272232
- -4.6% vs -2% NCT01272232
- -7.7% vs -6.5% NCT03374956
- -6.1% vs -1.9% NCT01272219
- 0.7% vs 0.3% NCT01272219
- 2.9% vs 0.3% NCT01272219
- -8.4% vs -3.1% NCT01272219
- -6.8% vs -3.1% NCT01272219
- -4.7% vs -2.7% NCT01272232
- -3.6% vs -2.7% NCT01272232
- -5.7% vs -1.4% NCT03480022
- -0.4% vs 3.3% NCT02527200
- 6.3% vs 3.3% NCT02527200
- 2.6% vs 3.3% NCT02527200
- -1.7% vs -1.2% NCT02527200
- -1.1% vs -1.2% NCT02527200
- -1.4% vs -1.2% NCT02527200
- -3.3% vs 0.2% NCT03158805
- -6.6% vs -1.2% NCT03038620
- orforglipron
- -7.9% vs -0.6%−7.3 vs placeboNCT05931380
11 other results
- -8.7% vs -0.6% NCT05931380
- -5.9% vs -0.6% NCT05931380
- -12.3% vs -2% NCT05051579
- -8.6% vs -2% NCT05051579
- -12.6% vs -2% NCT05051579
- -11.2% vs -2% NCT05051579
- -13.5% vs -2.3% NCT05051579
- -9.4% vs -2.3% NCT05051579
- -14.7% vs -2.3% NCT05051579
- -12.5% vs -2.3% NCT05051579
- -9.6% vs -2.5% NCT05872620
Weight loss of 5% or more
- Liraglutide (Saxenda)
- 63.2% vs 27.1%+36.1 vs placeboNCT01272219
4 other results
- 50.5% vs 21.9% NCT00781937
- 49.9% vs 13.8% NCT01272232
- 35.6% vs 13.8% NCT01272232
- 76% vs 17% NCT03048578
- orforglipron
- 58.3% vs 15%+43.3 vs placeboNCT05931380
10 other results
- 61.4% vs 15% NCT05931380
- 45.9% vs 15% NCT05931380
- 92.0% vs 24.0% NCT05051579
- 89.5% vs 22.9% NCT05051579
- 72% vs 24.0% NCT05051579
- 74.4% vs 22.9% NCT05051579
- 90.4% vs 24.0% NCT05051579
- 87.3% vs 22.9% NCT05051579
- 89.5% vs 24.0% NCT05051579
- 88.8% vs 22.9% NCT05051579
Weight loss of 10% or more
- Liraglutide (Saxenda)
- 33.1% vs 10.6%+22.5 vs placeboNCT01272219
3 other results
- 23.4% vs 4.3% NCT01272232
- 14.4% vs 4.3% NCT01272232
- 26.1% vs 6.3% NCT00781937
- orforglipron
- 38.3% vs 3.3%+35 vs placeboNCT05931380
10 other results
- 35.1% vs 3.3% NCT05931380
- 18.0% vs 3.3% NCT05931380
- 74.8% vs 8.8% NCT05051579
- 71.3% vs 2.3% NCT05051579
- 46.5% vs 8.8% NCT05051579
- 39.4% vs 2.3% NCT05051579
- 69.1% vs 8.8% NCT05051579
- 69.9% vs 2.3% NCT05051579
- 61.9% vs 8.8% NCT05051579
- 56.6% vs 2.3% NCT05051579
Waist circumference, change (cm)
- Liraglutide (Saxenda)
- -6.9 vs -3.4−3.5 vs placeboNCT01272219
24 other results
- -8.2 vs -3.9 NCT01272219
- -5.7 vs -3.2 NCT01272232
- -4.4 vs -0.9 NCT00781937
- -6.1 vs -2.7 NCT01272232
- -4.4 vs -3.2 NCT01272232
- -4.8 vs -2.7 NCT01272232
- 100.9 vs 109.9 NCT03480022
- -3.0 vs -2.1 NCT02527200
- 0.5 vs -2.1 NCT02527200
- -1.5 vs -2.1 NCT02527200
- -2.5 vs -1.9 NCT02527200
- -0.7 vs -1.9 NCT02527200
- -1.7 vs -1.9 NCT02527200
- -7.4 vs -4.6 NCT03038620
- -9.8 vs -9.5 NCT00422058
- -7.9 vs -6 NCT00422058
- -9 vs -9.5 NCT00422058
- -5.9 vs -6 NCT00422058
- -10 vs -9.5 NCT00422058
- -10.4 vs -9.5 NCT00422058
- -4.2 vs -6 NCT00422058
- -7.2 vs -6 NCT00422058
- -8.6 vs -9.5 NCT00422058
- -5.8 vs -6 NCT00422058
- orforglipron
- -5.7 vs -0.1−5.6 vs placeboNCT05931380
12 other results
- -5.9 vs -0.1 NCT05931380
- -3.7 vs -0.1 NCT05931380
- -10.6 vs -4 NCT05051579
- -10.1 vs -3.6 NCT05051579
- -9.6 vs -4 NCT05051579
- -8 vs -3.6 NCT05051579
- -13.6 vs -4 NCT05051579
- -12.2 vs -3.6 NCT05051579
- -11.2 vs -4 NCT05051579
- -8.8 vs -3.6 NCT05051579
- -5.8 NCT06023095
- -11.7 NCT06023095
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. Liraglutide (Saxenda): 10 of 10 rows · orforglipron: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Liraglutide (Saxenda) Rows use multiple source trials | orforglipron Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | -1.9 vs 0.15 placebo kg @ 56wk3.0 mga,b,c NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 | -2.63 vs -0.21 placebo kg @ 72wk36 mg QDd,a,b,c NCT05931380 · Phase 3 · registry result, not featured evidence show 2 more doses-2.83 vs -0.21 placebo kg @ 72wk12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence -1.94 vs -0.21 placebo kg @ 72wk6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence |
| Fasting Plasma Glucose absolute change · mmol/L | -0.23 vs 0.02 Orlistat mmol/L @ 104wk3.0 mgd,e,a,b,f NCT00422058 · Phase 2 · registry result, not featured evidence show 4 more doses-0.09 vs 0.02 Orlistat mmol/L @ 104wk1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.2 vs 0.02 Orlistat mmol/L @ 104wk2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.22 vs 0.02 Orlistat mmol/L @ 104wkplacebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.09 vs 0.02 Orlistat mmol/L @ 104wk1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence | -0.5 vs NA placebo mmol/Ld,e,a,b,f NCT06023095 · Phase 1 · registry result, not featured evidence show 1 more dose-0.17 vs NA placebo mmol/L NCT06023095 · Phase 1 · registry result, not featured evidence |
| HbA1c absolute change · percentage points | -0.35% (n=47) vs -0.18% (n=45) Orlistat @ 104wk3.0 mgd,g,h,b,i NCT00422058 · Phase 2 · registry result, not featured evidence show 4 more doses-0.3% (n=36) vs -0.18% (n=45) Orlistat @ 104wk1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.25% (n=45) vs -0.18% (n=45) Orlistat @ 104wk2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.32% (n=46) vs -0.18% (n=45) Orlistat @ 104wkplacebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -0.25% (n=45) vs -0.18% (n=45) Orlistat @ 104wk1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence | -1.66% vs -0.47% placebo @ 72wkorforglipron 17.2 mgg,h,b,i NCT05872620 · Phase 3 · sponsor-reported, not registry data 3 other source trials-0.61% (n=57) vs 0.041% (n=60) placebo @ 72wk12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence -0.62% (n=60) vs 0.041% (n=60) placebo @ 72wk36 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence -0.53% (n=61) vs 0.041% (n=60) placebo @ 72wk6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence |
| SBP absolute change · mmHg | -2 vs -1 placebo mmHg @ 56wk3.0 mga,b,c NCT02963935 · Phase 3 · registry result, not featured evidence | -4.36 vs -0.055 placebo mmHg @ 72wk36 mg QDd,a,b,c NCT05931380 · Phase 3 · registry result, not featured evidence show 2 more doses-3.84 vs -0.055 placebo mmHg @ 72wk12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence -5.08 vs -0.055 placebo mmHg @ 72wk6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg | -8.2 vs -3.8 Orlistat kg @ 104wk3.0 mgd,a,b,j NCT00422058 · Phase 2 · registry result, not featured evidence show 4 more doses-5.6 vs -3.8 Orlistat kg @ 104wk1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -6.4 vs -3.8 Orlistat kg @ 104wk2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -5.4 vs -3.8 Orlistat kg @ 104wkplacebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence -4.9 vs -3.8 Orlistat kg @ 104wk1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence | -14.2 vs -2.4 placebo kg @ 36wk36 mgd,a,b,j NCT05051579 · Phase 2 · registry result, not featured evidence show 3 more doses-9.8 vs -2.4 placebo kg @ 36wk12 mg NCT05051579 · Phase 2 · registry result, not featured evidence -15.4 vs -2.4 placebo kg @ 36wk45 mg NCT05051579 · Phase 2 · registry result, not featured evidence -13.6 vs -2.4 placebo kg @ 36wk24 mg NCT05051579 · Phase 2 · registry result, not featured evidence |
| Weight absolute change · kg No placebo or comparator arm | -6.51 kg @ 104wk3 mgk,a,b,l NCT03036800 · Phase 4 · registry result, not featured evidence · combination | -4.2 kg @ 4.14wkd,k,a,b,l NCT05313802 · Phase 1 · registry result, not featured evidence show 2 more doses-5.5 kg @ 4.14wk NCT05313802 · Phase 1 · registry result, not featured evidence -3.6 kg @ 4.14wk NCT05313802 · Phase 1 · registry result, not featured evidence |
| Dropout rate | 25%3.0 mgm NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 38 more results27.4%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 29.2%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 23.4%3.0 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 22.3%1.8 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 25.6%3.0 mg NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 10.4%3.0 mg NCT02918279 · Phase 3 22.7%3 mg NCT03036800 · Phase 4 · registry result, not featured evidence · combination 34.8% NCT03048578 · Phase 4 · registry result, not featured evidence 20.7%3.0 mg NCT03038620 · Phase 4 · registry result, not featured evidence 10% NCT02911818 · Phase 4 · registry result, not featured evidence — NCT01562678 · Phase 4 · registry result, not featured evidence 0% NCT03115424 · Phase 3 · registry result, not featured evidence 0% NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 20%3 mg NCT03480022 · Phase 3 · registry result, not featured evidence 15%Part A: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 11.8%Part B: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 16.2%3.0 mg NCT02963922 · Phase 3 · registry result, not featured evidence —3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 19.7%3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 31.4% NCT01784965 · Phase 3 · registry result, not featured evidence 8.8% NCT04883346 · Phase 2 · registry result, not featured evidence 55.2% NCT03158805 · Phase 2 · registry result, not featured evidence 11.9% NCT03523273 · Phase 2 · registry result, not featured evidence 10.5% NCT02647944 · Phase 2 · registry result, not featured evidence 11.8%3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 17.8%1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 21.5%2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 19.4%placebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 10.5%1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 16.7%420 mg NCT03757130 · Phase 1 · registry result, not featured evidence 16.7%AMG 598 420 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%210 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 210 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%70 mg NCT03757130 · Phase 1 · registry result, not featured evidence 12.5%AMG 598 70 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 12.5% NCT03041792 · Phase 1 · registry result, not featured evidence | 10%36 mg QDn NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results8.8%12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 11.5%6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 12%12 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 13.2%24 mg NCT05051579 · Phase 2 · registry result, not featured evidence —17.2 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —14.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —9 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —5.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —2.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —0.8 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 1) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 2) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 3) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 4) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 5) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 6) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 7) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 8) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 9) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 10) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 12) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 13) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 14) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 15) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 16) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 18) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 11) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 17) NCT06440980 · Phase 1 · registry result, not featured evidence 10%LY3502970 (Cohort 1) NCT06023095 · Phase 1 · registry result, not featured evidence 10%LY3502970 (Cohort 2) NCT06023095 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg + 0.2 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg DF capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg EPB capsule NCT05841238 · Phase 1 · registry result, not featured evidence —60 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —45 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —20 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —16 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —10 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —8 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —0.8 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 1 NCT05313802 · Phase 1 · registry result, not featured evidence 4.2%LY3502970 Cohort 2 NCT05313802 · Phase 1 · registry result, not featured evidence 8.3%LY3502970 Cohort 3 NCT05313802 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 8.5%3.0 mgm NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 38 more results9.9%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 9%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 9.2%3.0 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 8.5%1.8 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 11.1%3.0 mg NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT02918279 · Phase 3 —3 mg NCT03036800 · Phase 4 · registry result, not featured evidence · combination 1.1% NCT03048578 · Phase 4 · registry result, not featured evidence —3.0 mg NCT03038620 · Phase 4 · registry result, not featured evidence — NCT02911818 · Phase 4 · registry result, not featured evidence — NCT01562678 · Phase 4 · registry result, not featured evidence — NCT03115424 · Phase 3 · registry result, not featured evidence — NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 10.9%3 mg NCT03480022 · Phase 3 · registry result, not featured evidence —Part A: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence —Part B: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 7.6%3.0 mg NCT02963922 · Phase 3 · registry result, not featured evidence —3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 8.5%3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 22.9% NCT01784965 · Phase 3 · registry result, not featured evidence — NCT04883346 · Phase 2 · registry result, not featured evidence — NCT03158805 · Phase 2 · registry result, not featured evidence — NCT03523273 · Phase 2 · registry result, not featured evidence 10.5% NCT02647944 · Phase 2 · registry result, not featured evidence 5.4%3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 5.6%1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 9.7%2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 3.1%placebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 4.2%1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence —420 mg NCT03757130 · Phase 1 · registry result, not featured evidence —AMG 598 420 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination —210 mg NCT03757130 · Phase 1 · registry result, not featured evidence —AMG 598 210 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination —70 mg NCT03757130 · Phase 1 · registry result, not featured evidence —AMG 598 70 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 12.5% NCT03041792 · Phase 1 · registry result, not featured evidence | 3.3%36 mg QDn NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results3.5%12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 1.6%6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence —36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 4%12 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence —45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 1.9%24 mg NCT05051579 · Phase 2 · registry result, not featured evidence —17.2 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —14.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —9 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —5.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —2.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence —0.8 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 1) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 2) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 3) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 4) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 5) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 6) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 7) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 8) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 9) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 10) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 12) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 13) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 14) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 15) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 16) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 18) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 11) NCT06440980 · Phase 1 · registry result, not featured evidence —tablet QD (dose level 17) NCT06440980 · Phase 1 · registry result, not featured evidence 0%LY3502970 (Cohort 1) NCT06023095 · Phase 1 · registry result, not featured evidence 10%LY3502970 (Cohort 2) NCT06023095 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg + 0.2 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —1 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination —1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg DF capsule NCT05841238 · Phase 1 · registry result, not featured evidence —36 mg EPB capsule NCT05841238 · Phase 1 · registry result, not featured evidence —60 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —45 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —20 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —16 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —10 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —8 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence —2 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence —0.8 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 1 NCT05313802 · Phase 1 · registry result, not featured evidence 4.2%LY3502970 Cohort 2 NCT05313802 · Phase 1 · registry result, not featured evidence 4.2%LY3502970 Cohort 3 NCT05313802 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 4.2%3.0 mgm NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 38 more results15.1%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 6.2%3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3 —3.0 mg NCT01272219 · Phase 3 · Obesity · phase 3 8.8%3.0 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 8.6%1.8 mg NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 3.4%3.0 mg NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 2.4%3.0 mg NCT02918279 · Phase 3 16.5%3 mg NCT03036800 · Phase 4 · registry result, not featured evidence · combination 4.5% NCT03048578 · Phase 4 · registry result, not featured evidence 0%3.0 mg NCT03038620 · Phase 4 · registry result, not featured evidence 0% NCT02911818 · Phase 4 · registry result, not featured evidence 0% NCT01562678 · Phase 4 · registry result, not featured evidence 8.3% NCT03115424 · Phase 3 · registry result, not featured evidence 0% NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 0%3 mg NCT03480022 · Phase 3 · registry result, not featured evidence 5%Part A: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 11.8%Part B: Liraglutide NCT02527200 · Phase 3 · registry result, not featured evidence 8.2%3.0 mg NCT02963922 · Phase 3 · registry result, not featured evidence 4.2%3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence —3.0 mg NCT02963935 · Phase 3 · registry result, not featured evidence 22.9% NCT01784965 · Phase 3 · registry result, not featured evidence 0% NCT04883346 · Phase 2 · registry result, not featured evidence 0% NCT03158805 · Phase 2 · registry result, not featured evidence 1.5% NCT03523273 · Phase 2 · registry result, not featured evidence 0% NCT02647944 · Phase 2 · registry result, not featured evidence 10.8%3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 11.1%1.8 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 7.5%2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 6.1%placebo / 2.4 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 9.5%1.2 mg / 3.0 mg NCT00422058 · Phase 2 · registry result, not featured evidence 0%420 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 420 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%210 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 210 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0%70 mg NCT03757130 · Phase 1 · registry result, not featured evidence 0%AMG 598 70 mg + Liraglutide NCT03757130 · Phase 1 · registry result, not featured evidence · combination 0% NCT03041792 · Phase 1 · registry result, not featured evidence | 10%36 mg QDn NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results5.3%12 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 1.6%6 mg QD NCT05931380 · Phase 3 · registry result, not featured evidence 0%36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 10.3%36 mg NCT05051579 · Phase 2 · registry result, not featured evidence 0%12 mg NCT05051579 · Phase 2 · registry result, not featured evidence 6.5%45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05051579 · Phase 2 · registry result, not featured evidence 3.8%24 mg NCT05051579 · Phase 2 · registry result, not featured evidence 0%17.2 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0.6%36 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%12 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0.5%6 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%24 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%14.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%9 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0.5%5.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%3 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%2.5 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%1 mg capsule QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%0.8 mg tablet QD NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 1) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 2) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 3) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 4) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 5) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 6) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 7) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 8) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 9) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 10) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 12) NCT06440980 · Phase 1 · registry result, not featured evidence 2%tablet QD (dose level 13) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 14) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 15) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 16) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 18) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 11) NCT06440980 · Phase 1 · registry result, not featured evidence 0%tablet QD (dose level 17) NCT06440980 · Phase 1 · registry result, not featured evidence 0%LY3502970 (Cohort 1) NCT06023095 · Phase 1 · registry result, not featured evidence 0%LY3502970 (Cohort 2) NCT06023095 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 5.3%12 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%6 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg + 0.2 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 0.25 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%36 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%24 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%20 mg + 20 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%3 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%1 mg + 1000 mg NCT06186622 · Phase 1 · registry result, not featured evidence · combination 0%1 mg QD NCT06186622 · Phase 1 · registry result, not featured evidence 0%36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 2.2%36 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%36 mg DF capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%36 mg EPB capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%60 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%45 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%37.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%35 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 2.2%20 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%16 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%10 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%8 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%2.5 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%2 mg capsule NCT05841238 · Phase 1 · registry result, not featured evidence 0%0.8 mg tablet NCT05841238 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 1 NCT05313802 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 2 NCT05313802 · Phase 1 · registry result, not featured evidence 0%LY3502970 Cohort 3 NCT05313802 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 3.0 mgm nausea 47.6% (placebo 17.1%) constipation 26.9% (placebo 12.4%) diarrhoea 17.9% (placebo 12.4%) NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3 show 35 more results3.0 mg nausea 40.8% (placebo 17%) nasopharyngitis 26.5% (placebo 27.8%) diarrhoea 25.5% (placebo 14.2%) NCT01272219 · Phase 3 · Obesity · phase 3 3.0 mg nausea 43.7% (placebo 17%) constipation 21.2% (placebo 11.3%) diarrhoea 21% (placebo 14.2%) NCT01272219 · Phase 3 · Obesity · phase 3 3.0 mg hypoglycaemia 44.3% (placebo 27.8%) nausea 32.7% (placebo 13.7%) diarrhoea 25.6% (placebo 12.7%) NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 1.8 mg hypoglycaemia 40% (placebo 27.8%) nausea 31.4% (placebo 13.7%) diarrhoea 17.6% (placebo 12.7%) NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3 3.0 mg nausea 26.7% (placebo 6.7%) diarrhoea 16.5% (placebo 7.8%) headache 14.2% (placebo 11.2%) NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3 3.0 mg nausea 42.4% (placebo 14.3%) vomiting 34.4% (placebo 4%) nasopharyngitis 27.2% (placebo 30.2%) NCT02918279 · Phase 3 3 mg nausea 41.9% gastrointestinal hypomotility 35.8% diarrhoea 27.7% NCT03036800 · Phase 4 · registry result, not featured evidence · combination nausea 23.6% (placebo 7%) constipation 15.7% (placebo 9.3%) abdominal pain 9% (placebo 2.3%) NCT03048578 · Phase 4 · registry result, not featured evidence 3.0 mg gi related 46.7% (placebo 12.9%) respiratory tract infection 10.9% (placebo 15.1%) injection site reaction 7.6% (placebo 8.6%) NCT03038620 · Phase 4 · registry result, not featured evidence nausea 36% (placebo 4.3%) upper respiratory infection 32% (placebo 8.7%) constipation 30% (placebo 0%) NCT02911818 · Phase 4 · registry result, not featured evidence nausea 25% (placebo 25%) NCT01562678 · Phase 4 · registry result, not featured evidence nausea 16.7% (placebo 11.1%) vomiting 16.7% (placebo 11.1%) hgb < 11.5 g/dl 0% (placebo 0%) NCT03115424 · Phase 3 · registry result, not featured evidence during study 24.7% (placebo 25%) NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3 3 mg nausea 25.5% (placebo 11.1%) vomiting 9.1% (placebo 0%) diarrhea 7.3% (placebo 0%) NCT03480022 · Phase 3 · registry result, not featured evidence diarrhoea 50% (placebo 16.7%) abdominal pain 30% (placebo 25%) constipation 15% (placebo 0%) NCT02527200 · Phase 3 · registry result, not featured evidence diarrhoea 41.2% (placebo 16.7%) abdominal pain 17.6% (placebo 25%) abdominal pain upper 17.6% (placebo 0%) NCT02527200 · Phase 3 · registry result, not featured evidence 3.0 mg nausea 29.7% (placebo 11.7%) diarrhoea 23.1% (placebo 15.2%) nasopharyngitis 21.5% (placebo 18.3%) NCT02963922 · Phase 3 · registry result, not featured evidence 3.0 mg nausea 47.9% (placebo 17.9%) constipation 30.3% (placebo 18.6%) vomiting 23.2% (placebo 5%) NCT02963935 · Phase 3 · registry result, not featured evidence elective back surgery 2.9% (placebo 0%) family issues 2.9% (placebo 0%) protocol deviation 2.9% (placebo 0%) NCT01784965 · Phase 3 · registry result, not featured evidence dyspepsia 23.5% constipation 11.8% fatigue 11.8% NCT04883346 · Phase 2 · registry result, not featured evidence nausea 65.5% (placebo 45.2%) constipation 41.4% (placebo 9.7%) heartburn 34.5% (placebo 6.5%) NCT03158805 · Phase 2 · registry result, not featured evidence nausea 59.7% (placebo 15.9%) diarrhea 34.3% (placebo 8.7%) abdominal pain/discomfort 28.4% (placebo 5.8%) NCT03523273 · Phase 2 · registry result, not featured evidence nausea 63.2% (placebo 9.5%) headache 26.3% (placebo 19%) abdominal pain/discomfort 21.1% (placebo 9.5%) NCT02647944 · Phase 2 · registry result, not featured evidence 3.0 mg nausea 50.5% nasopharyngitis 40.9% headache 23.7% NCT00422058 · Phase 2 · registry result, not featured evidence 1.8 mg / 3.0 mg nasopharyngitis 37.8% nausea 37.8% gastroenteritis 22.2% NCT00422058 · Phase 2 · registry result, not featured evidence 2.4 mg / 3.0 mg nasopharyngitis 45.2% nausea 41.9% headache 24.7% NCT00422058 · Phase 2 · registry result, not featured evidence placebo / 2.4 mg / 3.0 mg nasopharyngitis 41.8% nausea 29.6% headache 23.5% NCT00422058 · Phase 2 · registry result, not featured evidence 1.2 mg / 3.0 mg nasopharyngitis 38.9% nausea 36.8% influenza 25.3% NCT00422058 · Phase 2 · registry result, not featured evidence 420 mg abdominal pain 0% (placebo 0%) arthralgia 0% (placebo 0%) back pain 0% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence nausea 50% (placebo 0%) diarrhoea 33.3% (placebo 0%) upper respiratory tract infection 33.3% (placebo 16.7%) NCT03757130 · Phase 1 · registry result, not featured evidence · combination 210 mg upper respiratory tract infection 50% (placebo 16.7%) arthralgia 16.7% (placebo 0%) blood creatine phosphokinase increased 16.7% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence upper respiratory tract infection 66.7% (placebo 16.7%) constipation 33.3% (placebo 0%) early satiety 33.3% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence · combination 70 mg back pain 16.7% (placebo 0%) constipation 16.7% (placebo 0%) diarrhoea 16.7% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence decreased appetite 62.5% (placebo 0%) lipase increased 37.5% (placebo 0%) nausea 25% (placebo 0%) NCT03757130 · Phase 1 · registry result, not featured evidence · combination nausea 46.9% (placebo 3.6%) diarrhoea 34.4% (placebo 14.3%) headache 34.4% (placebo 10.7%) NCT03041792 · Phase 1 · registry result, not featured evidence | 36 mg QDn nausea 33.3% (placebo 0%) constipation 31.7% (placebo 8.3%) nasopharyngitis 20% (placebo 35%) NCT05931380 · Phase 3 · registry result, not featured evidence show 97 more results12 mg QD nasopharyngitis 42.1% (placebo 35%) constipation 28.1% (placebo 8.3%) nausea 15.8% (placebo 0%) NCT05931380 · Phase 3 · registry result, not featured evidence 6 mg QD constipation 36.1% (placebo 8.3%) nasopharyngitis 26.2% (placebo 35%) diarrhoea 14.8% (placebo 3.3%) NCT05931380 · Phase 3 · registry result, not featured evidence 36 mg nausea 41.4% (placebo 10%) constipation 27.6% (placebo 6%) vomiting 27.6% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 36 mg nausea 48.3% (placebo 10%) constipation 24.1% (placebo 6%) covid-19 24.1% (placebo 18%) NCT05051579 · Phase 2 · registry result, not featured evidence 12 mg nausea 50% (placebo 10%) vomiting 26% (placebo 6%) constipation 24% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 45 mg nausea 41.9% (placebo 10%) vomiting 29% (placebo 6%) constipation 19.4% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 45 mg nausea 36.7% (placebo 10%) diarrhoea 33.3% (placebo 10%) vomiting 26.7% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 24 mg nausea 58.5% (placebo 10%) diarrhoea 35.8% (placebo 10%) constipation 32.1% (placebo 6%) NCT05051579 · Phase 2 · registry result, not featured evidence 17.2 mg tablet QD vomiting 5.7% headache 3.4% nausea 3.4% NCT06440980 · Phase 1 · registry result, not featured evidence 36 mg capsule QD headache 6.7% constipation 4.4% dizziness 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence 36 mg capsule QD headache 15.9% vomiting 10.8% diarrhoea 6.3% NCT06440980 · Phase 1 · registry result, not featured evidence 12 mg capsule QD constipation 6% nausea 6% headache 4% NCT06440980 · Phase 1 · registry result, not featured evidence 12 mg capsule QD constipation 21% headache 19.4% nausea 17.2% NCT06440980 · Phase 1 · registry result, not featured evidence 6 mg capsule QD headache 8.7% dyspepsia 4.3% vomiting 4.3% NCT06440980 · Phase 1 · registry result, not featured evidence 6 mg capsule QD headache 12.3% nausea 9.4% dyspepsia 7.9% NCT06440980 · Phase 1 · registry result, not featured evidence 24 mg capsule QD headache 10% vomiting 6% abdominal pain 4% NCT06440980 · Phase 1 · registry result, not featured evidence 24 mg capsule QD nausea 17.1% diarrhoea 12.7% constipation 10.5% NCT06440980 · Phase 1 · registry result, not featured evidence 14.5 mg tablet QD headache 8.3% nausea 8.3% diarrhoea 6.7% NCT06440980 · Phase 1 · registry result, not featured evidence 9 mg tablet QD headache 9.7% constipation 9.1% vomiting 8.1% NCT06440980 · Phase 1 · registry result, not featured evidence 5.5 mg tablet QD headache 8.4% nausea 8.4% constipation 4.9% NCT06440980 · Phase 1 · registry result, not featured evidence 3 mg capsule QD nausea 4.3% decreased appetite 2.1% diarrhoea 2.1% NCT06440980 · Phase 1 · registry result, not featured evidence 3 mg capsule QD headache 17.6% nausea 13.8% constipation 9.5% NCT06440980 · Phase 1 · registry result, not featured evidence 2.5 mg tablet QD headache 8.1% constipation 6.2% nausea 6.2% NCT06440980 · Phase 1 · registry result, not featured evidence 1 mg capsule QD constipation 7.7% decreased appetite 1.9% eructation 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence 1 mg capsule QD constipation 27% headache 15.8% nausea 6% NCT06440980 · Phase 1 · registry result, not featured evidence 0.8 mg tablet QD constipation 8.9% headache 8.9% dyspepsia 4.7% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 1) constipation 9.6% diarrhoea 1.9% eructation 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 2) abdominal pain 3.8% diarrhoea 3.8% constipation 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 3) constipation 13.5% abdominal distension 1.9% dizziness 1.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 4) nausea 7.8% vomiting 7.8% constipation 5.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 5) nausea 8.3% dyspepsia 6.3% headache 6.3% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 6) diarrhoea 5.9% abdominal pain 3.9% constipation 3.9% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 7) nausea 6.5% dyspepsia 4.3% headache 4.3% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 8) dyspepsia 6.4% headache 4.3% nausea 4.3% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 9) nausea 10.9% abdominal distension 6.5% abdominal pain 6.5% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 10) constipation 8% diarrhoea 6% dyspepsia 6% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 12) nausea 8% headache 6% diarrhoea 4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 13) constipation 8.2% abdominal pain 4.1% diarrhoea 4.1% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 14) dizziness 12.2% headache 6.1% abdominal pain 4.1% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 15) nausea 8% constipation 4% diarrhoea 4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 16) heart rate increased 8.9% constipation 4.4% headache 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 18) constipation 6.7% diarrhoea 6.7% nausea 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 11) dyspepsia 6% constipation 4% diarrhoea 4% NCT06440980 · Phase 1 · registry result, not featured evidence tablet QD (dose level 17) nausea 13.3% headache 6.7% diarrhoea 4.4% NCT06440980 · Phase 1 · registry result, not featured evidence decreased appetite 70% (placebo 50%) diarrhoea 60% (placebo 25%) eructation 40% (placebo 0%) NCT06023095 · Phase 1 · registry result, not featured evidence nausea 80% (placebo 0%) decreased appetite 70% (placebo 50%) diarrhoea 70% (placebo 25%) NCT06023095 · Phase 1 · registry result, not featured evidence 36 mg constipation 4.5% diarrhoea 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg abdominal pain upper 4.5% dizziness 4.5% vomiting 4.5% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD back pain 4.5% diarrhoea 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD constipation 23.1% nausea 11.5% abdominal pain 7.7% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD constipation 22.2% alopecia 5.6% diarrhoea 5.6% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg QD anxiety 6.3% constipation 6.3% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence 12 mg QD alanine aminotransferase increased 3.8% aspartate aminotransferase increased 3.8% fatigue 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 12 mg QD back pain 5.3% constipation 5.3% cough 5.3% NCT06186622 · Phase 1 · registry result, not featured evidence 6 mg QD dyspepsia 7.7% nausea 7.7% diarrhoea 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 6 mg QD fatigue 15.8% eructation 10.5% headache 10.5% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg + 0.2 mg dizziness 4.8% headache 4.8% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 0.25 mg nausea 9.1% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg decreased appetite 4.5% headache 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 1000 mg headache 4.5% nausea 4.5% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg abdominal pain 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 0.25 mg constipation 6.3% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg abdominal pain upper 6.3% abdominal pain 0% alanine aminotransferase increased 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 36 mg + 20 mg dysmenorrhoea 6.3% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 24 mg QD abdominal pain 3.8% diarrhoea 3.8% headache 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 24 mg QD constipation 5.6% diarrhoea 5.6% eructation 5.6% NCT06186622 · Phase 1 · registry result, not featured evidence 20 mg + 20 mg alanine aminotransferase increased 9.1% aspartate aminotransferase increased 9.1% abdominal pain 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 20 mg + 20 mg alanine aminotransferase increased 12.5% aspartate aminotransferase increased 12.5% headache 6.3% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 3 mg QD diarrhoea 3.8% fatigue 3.8% nausea 3.8% NCT06186622 · Phase 1 · registry result, not featured evidence 3 mg QD abdominal pain 10% nausea 10% alanine aminotransferase increased 5% NCT06186622 · Phase 1 · registry result, not featured evidence 1 mg QD medication error 7.4% dysmenorrhoea 3.7% fatigue 3.7% NCT06186622 · Phase 1 · registry result, not featured evidence 1 mg + 1000 mg headache 3.7% abdominal pain 0% abdominal pain upper 0% NCT06186622 · Phase 1 · registry result, not featured evidence · combination 1 mg QD eructation 15% decreased appetite 10% headache 10% NCT06186622 · Phase 1 · registry result, not featured evidence 36 mg capsule nausea 9.5% abdominal pain 4.8% constipation 4.8% NCT05841238 · Phase 1 · registry result, not featured evidence 36 mg capsule diarrhoea 4.4% abdominal pain 2.2% abdominal distension 0% NCT05841238 · Phase 1 · registry result, not featured evidence 36 mg DF capsule constipation 8.3% diarrhoea 8.3% nausea 8.3% NCT05841238 · Phase 1 · registry result, not featured evidence 36 mg EPB capsule nausea 41.7% headache 16.7% diarrhoea 8.3% NCT05841238 · Phase 1 · registry result, not featured evidence 60 mg tablet vomiting 14.3% constipation 4.8% dyspepsia 4.8% NCT05841238 · Phase 1 · registry result, not featured evidence 45 mg tablet abdominal distension 9.5% nausea 9.5% vomiting 4.8% NCT05841238 · Phase 1 · registry result, not featured evidence 37.5 mg tablet headache 19% nausea 19% constipation 9.5% NCT05841238 · Phase 1 · registry result, not featured evidence 37.5 mg tablet nausea 14.6% headache 12.2% vomiting 12.2% NCT05841238 · Phase 1 · registry result, not featured evidence 35 mg tablet dyspepsia 14.3% flatulence 14.3% nausea 14.3% NCT05841238 · Phase 1 · registry result, not featured evidence 35 mg tablet intertrigo 14.3% abdominal distension 0% abdominal pain 0% NCT05841238 · Phase 1 · registry result, not featured evidence 20 mg tablet dyspepsia 4.3% abdominal pain 2.2% diarrhoea 2.2% NCT05841238 · Phase 1 · registry result, not featured evidence 16 mg capsule diarrhoea 6.5% vomiting 2.2% abdominal distension 0% NCT05841238 · Phase 1 · registry result, not featured evidence 10 mg tablet constipation 12.2% nausea 4.1% dyspepsia 2% NCT05841238 · Phase 1 · registry result, not featured evidence 8 mg capsule dyspepsia 10.2% decreased appetite 6.1% diarrhoea 6.1% NCT05841238 · Phase 1 · registry result, not featured evidence 5 mg tablet headache 12% dyspepsia 4% abdominal pain 2% NCT05841238 · Phase 1 · registry result, not featured evidence 2.5 mg tablet headache 4% decreased appetite 2% gastrooesophageal reflux disease 2% NCT05841238 · Phase 1 · registry result, not featured evidence 2 mg capsule constipation 10% diarrhoea 2% abdominal distension 0% NCT05841238 · Phase 1 · registry result, not featured evidence 0.8 mg tablet constipation 3.8% headache 3.8% nausea 3.8% NCT05841238 · Phase 1 · registry result, not featured evidence constipation 37.5% headache 33.3% weight decreased 25% NCT05313802 · Phase 1 · registry result, not featured evidence dyspepsia 41.7% constipation 33.3% weight decreased 29.2% NCT05313802 · Phase 1 · registry result, not featured evidence constipation 25% dyspepsia 25% headache 16.7% NCT05313802 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 72 weeks versus 56 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 1 versus Phase 2.
- fThe assessment timepoint is not available for both results.
- gTrial phases differ: Phase 3 versus Phase 2.
- hPopulation context differs: registered conditions differ.
- iAssessment timepoints differ: 72 weeks versus 104 weeks.
- jAssessment timepoints differ: 36 weeks versus 104 weeks.
- kTrial phases differ: Phase 1 versus Phase 4.
- lAssessment timepoints differ: 4.14 weeks versus 104 weeks.
- mPopulation comparability has not been reviewed for 30 of these studies.
- nPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Liraglutide (Saxenda)
show 1 more result
show 1 more result
show 1 more result
show 6 more results
show 10 more results
+ 179 further endpoints in the CSV export.
orforglipron
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Saxenda)'s landscape · orforglipron's landscape